Gujarat Inject (Kerala) Ltd.

BSE: GUJINJEC · Pharmaceuticals · sector

₹10.17BSE close 2026-10-26

Key numbers

Market cap₹15 cr

Price₹10.17

52w high / low₹137 / ₹9

P/E3.2xSector median 27.9x

P/B1.3xSector median 2.9x

Book value₹8.1

Dividend yield–Sector median 0.48%

ROE27.4%Sector median 11.7%

ROCE34.6%Sector median 12.3%

OPM8.4%Sector median 14.0%

Debt / equity0.00xSector median 0.16x

EV/EBITDA3.6xSector median 18.6x

Interest cover20,468.5x

Current ratio0.47x

Sales growth 3y+497.8%Sector median +9.6%

Profit growth 3y+256.6%Sector median +13.3%

PEG0.01x

Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹1 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
Operating profit covered interest 20,468.5x in the last 12 months.
Other income was 7% of net profit in the last 12 months.
No dividend in the last 5 financial years.
Price ₹10.17 on 2026-10-26: -92.6% from the 52-week high, +16.0% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹13.65 · low ₹9.18

Quarterly results

₹ cr	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	2	4	2	2	2	31	12
EBITDA	0	0	0	0	-0	2	2
OPM %	1.9%	2.1%	4.1%	1.9%	-5.5%	7.4%	13.6%
Other income	0	0	0	0	0	0	0
Net profit	0	0	0	0	0	2	1
EPS (₹)	0.05	0.05	0.05	0.05	0.03	2.24	0.86
Revenue YoY					+3.2%	+624.1%	+414.5%
Profit YoY					-42.9%	+2,242.9%	+1,685.7%

Standalone figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY22	FY23	FY24	FY25	FY26	TTM
Revenue	0	0	6	19	36	46
EBITDA	-0	-0	0	1	2	4
Net profit	0	0	0	1	2	3
EPS (₹)	–	0.08	0.07	0.70	2.48	3.18
Revenue growth		+750.0%	+3,305.9%	+229.0%	+90.7%	–
Profit growth		–	+100.0%	+1,175.0%	+77.5%	–
Dividend / share (₹)	–	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+497.8%	–	–
Net profit	+256.6%	–	–
EPS	+214.1%	–	–
Share price	–	-25.6% (2y)	-52.1%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	10	12
Borrowings	0	0
Cash & equivalents	2	1
Total assets	12	37
Fixed assets	0	0
Capital work in progress	0	21
Investments	0	0
Receivables	7	6
Inventory	0	0
Payables	2	20

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-4	21
Cash from investing	0	-21
Cash from financing	1	0
Capex	0	21
Free cash flow	-4	0

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	10.2%	15.3%
ROCE %	12.5%	21.2%
Debtor days	138	64
Inventory days	0	0
Payable days	34	220
Cash conversion cycle (days)	104	-156
Working capital days	138	-133

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
GUJINJEC	₹15 cr	3.2x	1.3x	27.4%	34.6%	8.4%	+497.8%	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	GUJINJEC
BSE code	524238
ISIN	INE659F01022
Face value	₹1.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.